Tipifarnib in HRAS-mutant Head and Neck Squamous Cell Carcinoma

home / news-network / tipifarnib-in-hras-mutant-head-and-neck-squamous-cell-carcinoma

Glenn Hanna, MD, and Nabil F. Saba, MD, FACP, discuss recent data on use of tipifarnib in HRAS-mutant head and neck squamous cell carcinoma.

EP. 1: The Evolving Treatment Landscape of HNSCC

By Glenn J. Hanna, MD, Dana-Farber Cancer Institute
Nabil F Saba, MD, FACP, Emory University

July 19th 2021

A brief overview of treatment advances for HRAS-mutated head and neck squamous cell carcinoma.

EP. 2: Molecular Testing in HNSCC

By Glenn J. Hanna, MD, Dana-Farber Cancer Institute
Nabil F Saba, MD, FACP, Emory University

July 19th 2021

Guidance for incorporating initial and repeat molecular testing in head and neck cancers into clinical practice.

EP. 3: Tipifarnib in HRAS-Mutated HNSCC

By Glenn J. Hanna, MD, Dana-Farber Cancer Institute
Nabil F Saba, MD, FACP, Emory University

July 19th 2021

Potential implications for treating patients with HRAS-mutated head and neck cancer with tipifarnib, based on results demonstrated by the RUN-HN study.

EP. 4: Pivotal AIM-HN Clinical Trial of Tipifarnib in HNSCC

By Glenn J. Hanna, MD, Dana-Farber Cancer Institute
Nabil F Saba, MD, FACP, Emory University

July 19th 2021

Glenn J. Hanna, MD, and Nabil F. Saba, MD, FACP, discuss the design and potential clinical implications of the AIM-HN trial of tipifarnib in head and neck cancers.

EP. 5: Future Directions in HRAS-Mutated Head and Neck Cancer

By Glenn J. Hanna, MD, Dana-Farber Cancer Institute
Nabil F Saba, MD, FACP, Emory University

July 19th 2021

Glenn J. Hanna, MD, and Nabil F. Saba, MD, FACP, highlight potential new therapies for head and neck squamous cell carcinoma in various patient populations.